Nascent Biotech, Inc.
NBIO · OTC
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $8,076 | $15,171 | $30,707 | $28,917 |
| - Cash | $2 | $47 | $372 | $624 |
| + Debt | $59 | $59 | $123 | $125 |
| Enterprise Value | $8,133 | $15,183 | $30,457 | $28,418 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | -100% | – | – |
| Gross Profit | $0 | -$115 | -$181 | $0 |
| % Margin | – | – | -5,361,374.4% | – |
| EBITDA | -$251 | -$375 | -$513 | -$364 |
| % Margin | – | – | -15,182,908.8% | – |
| Net Income | -$252 | -$377 | -$513 | -$205 |
| % Margin | – | – | -15,195,497.6% | – |
| EPS Diluted | -0.002 | -0.002 | -0.003 | -0.001 |
| % Growth | 31.8% | 26.7% | -150% | – |
| Operating Cash Flow | – | -$325 | -$352 | -$330 |
| Capital Expenditures | – | $0 | -$0 | $0 |
| Free Cash Flow | – | -$325 | -$352 | -$330 |